GSK plc
GSKNYSEHealthcare● Active
$51.52
+$0.25(+0.49%)
Market Cap$103.6B
P/E Ratio—
52W High$61.7
52W Low$35.45
GSK plc (GSK) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
GSK · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: Apr 29, 2026EPS Actual
$1.24
Est. $1.16 · +6.9%
Revenue
$10.30B
Est. $10.23B · +0.7%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
Apr 29, 2026
After Market Close
▲ Beat EPS🔥 7-Quarter EPS Beat Streak
GSK reports quarterly as a NYSE-listed Drug Manufacturers - General company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $7.60B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$7.60B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Jul 28, 2026 | $1.25 | — | — | — | $11.11B | — |
| ▲ Q2 FY2026 | Apr 29, 2026 | $1.16 | $1.24 | +6.9% | $10.30B | $10.23B | +0.7% |
| ▲ Q1 FY2026 | Feb 4, 2026 | $0.64 | $0.68 | +6.3% | $11.78B | $11.41B | +3.2% |
| ▲ Q4 FY2025 | Oct 29, 2025 | $1.26 | $1.48 | +17.5% | $8.55B | $8.48B | +0.8% |
| — Q3 FY2025 | Jul 30, 2025 | — | $0.96 | — | $10.88B | — | — |
| ▲ Q2 FY2025 | Apr 30, 2025 | $1.08 | $1.13 | +4.6% | $9.70B | $7.95B | +22.1% |
| ▲ Q1 FY2025 | Feb 5, 2025 | $0.44 | $0.59 | +34.1% | $10.16B | $9.54B | +6.5% |
| ▲ Q4 FY2024 | Oct 30, 2024 | $1.16 | $1.27 | +9.5% | $10.50B | $10.10B | +3.9% |
Q3 FY2026
Jul 28, 2026
EPS Actual
—
EPS Est.
$1.25
EPS Surpr.
—
Revenue
—
Q2 FY2026
Apr 29, 2026Beat
EPS Actual
$1.24
EPS Est.
$1.16
EPS Surpr.
+6.9%
Revenue
$10.30B
Q1 FY2026
Feb 4, 2026Beat
EPS Actual
$0.68
EPS Est.
$0.64
EPS Surpr.
+6.3%
Revenue
$11.78B
Q4 FY2025
Oct 29, 2025Beat
EPS Actual
$1.48
EPS Est.
$1.26
EPS Surpr.
+17.5%
Revenue
$8.55B
Q3 FY2025
Jul 30, 2025
EPS Actual
$0.96
EPS Est.
—
EPS Surpr.
—
Revenue
$10.88B
Q2 FY2025
Apr 30, 2025Beat
EPS Actual
$1.13
EPS Est.
$1.08
EPS Surpr.
+4.6%
Revenue
$9.70B
Q1 FY2025
Feb 5, 2025Beat
EPS Actual
$0.59
EPS Est.
$0.44
EPS Surpr.
+34.1%
Revenue
$10.16B
Q4 FY2024
Oct 30, 2024Beat
EPS Actual
$1.27
EPS Est.
$1.16
EPS Surpr.
+9.5%
Revenue
$10.50B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.77 | $0.80 | $0.84 | 1 |
| Q3 FY2027 | $1.54 | $1.60 | $1.67 | 1 |
| Q2 FY2027 | $1.28 | $1.33 | $1.39 | 1 |
| Q1 FY2027 | $1.29 | $1.34 | $1.40 | 1 |
| Q4 FY2026 | $0.77 | $0.81 | $0.84 | 1 |
| Q3 FY2026 | $1.28 | $1.44 | $1.72 | 3 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $12.0B | $12.3B | $12.8B | 2 |
| Q3 FY2027 | $11.9B | $12.3B | $12.7B | 2 |
| Q2 FY2027 | $11.1B | $11.4B | $11.8B | 2 |
| Q1 FY2027 | $10.3B | $10.7B | $11.0B | 2 |
| Q4 FY2026 | $11.7B | $12.0B | $12.4B | 2 |
| Q3 FY2026 | $11.4B | $12.0B | $12.5B | 5 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | Apr 29, 2026 | +6.9% | $54.47 | $51.40 | -5.64% |
| ▲ Q1 FY2026 | Feb 4, 2026 | +6.3% | $53.34 | $57.23 | +7.29% |
| ▲ Q4 FY2025 | Oct 29, 2025 | +17.5% | $43.70 | $45.93 | +5.10% |
| — Q3 FY2025 | Jul 30, 2025 | — | $37.67 | $38.97 | +3.45% |
| ▲ Q2 FY2025 | Apr 30, 2025 | +4.6% | $38.97 | $39.85 | +2.26% |
| ▲ Q1 FY2025 | Feb 5, 2025 | +34.1% | $34.84 | $37.70 | +8.21% |
| ▲ Q4 FY2024 | Oct 30, 2024 | +9.5% | $38.17 | $37.01 | -3.04% |
| ▲ Q3 FY2024 | Jul 31, 2024 | +9.0% | $39.77 | $38.77 | -2.51% |
Q2 FY2026-5.64%
Report Date
Apr 29, 2026
EPS Beat/Miss
+6.9%
Price Before
$54.47
Price After
$51.40
Q1 FY2026+7.29%
Report Date
Feb 4, 2026
EPS Beat/Miss
+6.3%
Price Before
$53.34
Price After
$57.23
Q4 FY2025+5.10%
Report Date
Oct 29, 2025
EPS Beat/Miss
+17.5%
Price Before
$43.70
Price After
$45.93
Q3 FY2025+3.45%
Report Date
Jul 30, 2025
EPS Beat/Miss
—
Price Before
$37.67
Price After
$38.97
Q2 FY2025+2.26%
Report Date
Apr 30, 2025
EPS Beat/Miss
+4.6%
Price Before
$38.97
Price After
$39.85
Q1 FY2025+8.21%
Report Date
Feb 5, 2025
EPS Beat/Miss
+34.1%
Price Before
$34.84
Price After
$37.70
Q4 FY2024-3.04%
Report Date
Oct 30, 2024
EPS Beat/Miss
+9.5%
Price Before
$38.17
Price After
$37.01
Q3 FY2024-2.51%
Report Date
Jul 31, 2024
EPS Beat/Miss
+9.0%
Price Before
$39.77
Price After
$38.77
Avg Beat Reaction+1.67%
Beat Rate7 / 8 quarters
Largest Move+8.21% (Q1 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: GSK ends December
GSK plc (GSK) most recently reported earnings on April 29, 2026 for Q2 FY2026, posting EPS of $1.24 — beating the analyst consensus of $1.16 by +6.9%. GSK has beaten EPS estimates for 7 consecutive quarters. The next GSK earnings date is expected around September 1, 2026.
Each quarter, investors track GSK earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. GSK revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
GSK's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
GSK earnings · 5 questionsGSK plc's next earnings report is expected around September 1, 2026. GSK typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; GSK historically reports after market close (AMC).
GSK earnings datewhen is GSK earningsGSK next earnings datewhen does GSK report earningsGSK earnings calendar
▸ Source: FMP · GSK plc SEC filings · US GAAP · GSK plc SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026